Navigation Links
SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal
Date:5/15/2009

Survey, please visit: http://www.SHARE-hypertension.com For more information on SHARE and The Challenging Patient, please visit: http://www.sevikar.com andhttp://www.challengingpatient.com References 1. WHO. The world health report 2002 2. Lawes CM, Vander Hoorn S, Rodgers A. Lancet 2008;371(9623):1513-8. 3. Allender et al. European Heart Network 2008 4. Redon etal. 2008 J Hypertens 26(12):S1-S14 5. ESH Scientific Newsletter 2007;8:No 3, http://www.eshonline.org/education/newsletter/2007_03.pdf

6. Neal et al Lancet 2000;356:1955-64, Prospective Studies Collaboration. Lancet 2002;360:1903-13

About DAIICHI SANKYO

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of more than 5.9 billion EUR in fiscal year 2008, DAIICHI SANKYO is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo, and its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries and has been one of the strongest Japanese pharmaceutical companies located in Europe since it set up European production facilities and marketing offices in 1990. The company's research activities focus on the areas of: cardiovascular diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to develop medications that are "best" in their class or to create new classes of pharmaceutical drugs. For more information, please visit: http://www.
'/>"/>

SOURCE DAIICHI SANKYO EUROPE GmbH and SHARE
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Schering-Plough Schedules Webcast For Annual Meeting of Shareholders
2. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
3. Arpida to Discuss Strategy With Shareholders
4. New Website Connects Physicians to Solve Challenging Cases and Share Experiences
5. Syrinx Wins Contract with Leading Pharmaceutical Company for SharePoint 2007 Services
6. Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment
7. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
8. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
9. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
10. Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA
11. Techne Corporation Declares Dividend and Announces an Increase in Its Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... SAN DIEGO , March 5, 2015  In ... Marketwired in Miami, FL on ... company are both of strong financial health and their ... as clinical research has indicated. Furthermore, Impeto prefers to have ... There are more than 40 articles written ...
(Date:3/5/2015)... Southlake, Texas (PRWEB) March 05, 2015 ... treatment of acute and chronic orthopedic conditions such ... runner’s knee, tennis elbow, and joint pain due ... also be administered during orthopedic surgeries to promote ... patented scientific advances in nearly pain-free bone marrow ...
(Date:3/4/2015)... , March 4, 2015 The UPMC Center ... 2015 Fellows in the Emerging Leaders in Biosecurity Initiative ... leaders in the field of biosecurity, UPMC has selected ... a wide array of backgrounds, including biological science, medicine, ... "With the vision and support of ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ) ... report "Biomarkers - Technologies, Markets and Companies" ... report follows the broad definition of a biomarker ... and evaluated as an indicator of normal biological ... to a therapeutic intervention. Tests based on biomarkers ...
Breaking Biology Technology:Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3
... Germany, March 10 febit,holding gmbh today announced ... created position of vice president, marketing and sales. ... which is located near Boston in,Medford, Mass., ... initiatives for febit,s,genomics technology products and services. These ...
... Switzerland, March 10 /PRNewswire-FirstCall/ - Anavex Life,Sciences Corp. ... demonstrated its ability to significantly delay the growth ... studies.,The human tumor xenografts were developed in ANAVEX ... from clear cell sarcoma. Clear cell sarcoma,is a ...
... Calif., March 10 Varian, Inc.,(NasdaqGS: VARI) announced ... resonance NMR applications involving liquid-state samples. The,OneNMR Probe ... to employ a single probe rather than switching ... for analytical and,research chemists performing a broad range ...
Cached Biology Technology:febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales 2Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 2Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 3Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 4Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 5Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 6Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses 2
(Date:2/19/2015)... .19, 2015 Research and Markets ... the "Military Electro-Optical / Infrared Systems Market ... Platform - Forecast to 2020" report to ... systems market is expected to reach $16.35 billion ... This report segments the military electro-optical/infrared ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... Never underestimate the power of Mom when it comes ... explains how motherly influence could be even more effective ... Knowlden, a former doctoral student at UC and current ... Department, hopes his research can better prepare moms to ...
... release is available in German . ... global impacts of land use on the environment and help ... of the Helmholtz Centre for Environmental Research (UFZ) has created ... various indicators of land-use intensity, climate, environmental and socio-economic conditions, ...
... earthquakes, major traffic accidents, and terrorist attacks may ... extreme fear and helplessness for people that have ... This persistent and constant mental disorder caused by ... Can brain structural damage alter as symptoms ...
Cached Biology News:Internet helps ensure mother knows best when it comes to preventing childhood obesity 2Internet helps ensure mother knows best when it comes to preventing childhood obesity 3Global map provides new insights into land use 2Global map provides new insights into land use 3
Chicken Anti-Human Stomatin-like 2 (STOML2 Polyclonal AntibodyNew Applications: ELISA, Western Blot...
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
... anti-Cytohesin 2, Monoclonal Antibody, Unconjugated ... dependent dilution. ICC: Use at an assay dependent ... - 10 ug/ml, this concentration is determined using ... weight: 40 kDa. Not tested in other applications. ...
Potassium Channel kv3.2...
Biology Products: